share_log

We Think Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076) Can Stay On Top Of Its Debt

We Think Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076) Can Stay On Top Of Its Debt

我們認爲江蘇中石油-艾爾西諾生物製藥(SHSE: 688076)可以繼續償還債務
Simply Wall St ·  05/21 11:50

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. We note that Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076) does have debt on its balance sheet. But the more important question is: how much risk is that debt creating?

大衛·伊本說得好,他說:“波動性不是我們關心的風險。我們關心的是避免資本的永久損失。”當你檢查公司的資產負債表的風險時,考慮它的資產負債表是很自然的,因爲企業倒閉時通常會涉及債務。我們注意到,江蘇賽諾普-艾爾西諾生物製藥有限公司(SHSE: 688076)的資產負債表上確實有債務。但更重要的問題是:這筆債務會帶來多大的風險?

When Is Debt A Problem?

債務何時會成爲問題?

Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. Part and parcel of capitalism is the process of 'creative destruction' where failed businesses are mercilessly liquidated by their bankers. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, debt can be an important tool in businesses, particularly capital heavy businesses. The first step when considering a company's debt levels is to consider its cash and debt together.

債務是幫助企業增長的工具,但是如果企業無法償還貸款,那麼債務就任其擺佈。資本主義的組成部分是 “創造性破壞” 過程,在這種過程中,倒閉的企業被銀行家無情地清算。但是,更頻繁(但仍然昂貴)的情況是,公司必須以低廉的價格發行股票,永久稀釋股東,以支撐其資產負債表。當然,債務可以成爲企業的重要工具,尤其是資本密集型企業。考慮公司的債務水平的第一步是同時考慮其現金和債務。

What Is Jiangsu Sinopep-Allsino Biopharmaceutical's Net Debt?

江蘇中諾普-艾爾西諾生物製藥的淨負債是多少?

The image below, which you can click on for greater detail, shows that at March 2024 Jiangsu Sinopep-Allsino Biopharmaceutical had debt of CN¥1.04b, up from CN¥418.7m in one year. However, because it has a cash reserve of CN¥744.2m, its net debt is less, at about CN¥295.5m.

您可以點擊下圖查看更多詳情,該圖片顯示,截至2024年3月,江蘇中石化-艾爾西諾生物製藥的債務爲10.4億元人民幣,高於一年的4.187億元人民幣。但是,由於其現金儲備爲7.442億元人民幣,其淨負債較少,約爲2.955億元人民幣。

debt-equity-history-analysis
SHSE:688076 Debt to Equity History May 21st 2024
SHSE: 688076 2024 年 5 月 21 日債務與股權比率的歷史記錄

How Strong Is Jiangsu Sinopep-Allsino Biopharmaceutical's Balance Sheet?

江蘇中諾普-艾爾西諾生物製藥的資產負債表有多強?

Zooming in on the latest balance sheet data, we can see that Jiangsu Sinopep-Allsino Biopharmaceutical had liabilities of CN¥1.06b due within 12 months and liabilities of CN¥387.3m due beyond that. Offsetting this, it had CN¥744.2m in cash and CN¥338.6m in receivables that were due within 12 months. So its liabilities total CN¥368.1m more than the combination of its cash and short-term receivables.

放大最新的資產負債表數據,我們可以看到,江蘇中石化-艾爾西諾生物製藥在12個月內到期的負債爲10.6億元人民幣,在此之後到期的負債爲3.873億元人民幣。與此相抵消的是,它有7.442億元的現金和3.386億元人民幣的應收賬款將在12個月內到期。因此,其負債總額比其現金和短期應收賬款的總額高出3.681億元人民幣。

Given Jiangsu Sinopep-Allsino Biopharmaceutical has a market capitalization of CN¥12.1b, it's hard to believe these liabilities pose much threat. However, we do think it is worth keeping an eye on its balance sheet strength, as it may change over time.

鑑於江蘇中諾寶-艾爾西諾生物製藥的市值爲121億元人民幣,很難相信這些負債會構成很大的威脅。但是,我們確實認爲值得關注其資產負債表的實力,因爲它可能會隨着時間的推移而發生變化。

In order to size up a company's debt relative to its earnings, we calculate its net debt divided by its earnings before interest, tax, depreciation, and amortization (EBITDA) and its earnings before interest and tax (EBIT) divided by its interest expense (its interest cover). Thus we consider debt relative to earnings both with and without depreciation and amortization expenses.

爲了擴大公司相對於收益的負債規模,我們計算其淨負債除以利息、稅項、折舊和攤銷前的收益(EBITDA),將其利息和稅前收益(EBIT)除以利息支出(利息保障)。因此,我們將債務與收益的關係考慮在內,包括和不包括折舊和攤銷費用。

Jiangsu Sinopep-Allsino Biopharmaceutical has a low net debt to EBITDA ratio of only 0.78. And its EBIT easily covers its interest expense, being 22.5 times the size. So you could argue it is no more threatened by its debt than an elephant is by a mouse. Better yet, Jiangsu Sinopep-Allsino Biopharmaceutical grew its EBIT by 159% last year, which is an impressive improvement. If maintained that growth will make the debt even more manageable in the years ahead. The balance sheet is clearly the area to focus on when you are analysing debt. But it is future earnings, more than anything, that will determine Jiangsu Sinopep-Allsino Biopharmaceutical's ability to maintain a healthy balance sheet going forward. So if you want to see what the professionals think, you might find this free report on analyst profit forecasts to be interesting.

江蘇中諾寶-艾爾西諾生物製藥的淨負債與息稅折舊攤銷前利潤的比率很低,僅爲0.78。而且其息稅前利潤很容易彌補其利息支出,是其規模的22.5倍。因此,你可以爭辯說,它受到債務的威脅並不比大象受到老鼠的威脅更大。更好的是,去年,江蘇華諾生物製藥的息稅前利潤增長了159%,這是一個令人印象深刻的改善。如果這種增長得以維持,將使未來幾年的債務更加易於管理。資產負債表顯然是分析債務時需要關注的領域。但是,未來的收益比什麼都重要,將決定江蘇中石化-艾爾西諾生物製藥未來維持健康資產負債表的能力。因此,如果你想看看專業人士的想法,你可能會發現這份關於分析師利潤預測的免費報告很有趣。

Finally, while the tax-man may adore accounting profits, lenders only accept cold hard cash. So the logical step is to look at the proportion of that EBIT that is matched by actual free cash flow. Over the last three years, Jiangsu Sinopep-Allsino Biopharmaceutical saw substantial negative free cash flow, in total. While investors are no doubt expecting a reversal of that situation in due course, it clearly does mean its use of debt is more risky.

最後,儘管稅務人員可能喜歡會計利潤,但貸款人只接受冷硬現金。因此,合乎邏輯的步驟是研究息稅前利潤與實際自由現金流相匹配的比例。在過去的三年中,江蘇華諾-艾爾西諾生物製藥的自由現金流總額爲負數。儘管投資者無疑預計這種情況將在適當的時候逆轉,但這顯然意味着其使用債務的風險更大。

Our View

我們的觀點

Jiangsu Sinopep-Allsino Biopharmaceutical's interest cover suggests it can handle its debt as easily as Cristiano Ronaldo could score a goal against an under 14's goalkeeper. But we must concede we find its conversion of EBIT to free cash flow has the opposite effect. Looking at all the aforementioned factors together, it strikes us that Jiangsu Sinopep-Allsino Biopharmaceutical can handle its debt fairly comfortably. Of course, while this leverage can enhance returns on equity, it does bring more risk, so it's worth keeping an eye on this one. There's no doubt that we learn most about debt from the balance sheet. But ultimately, every company can contain risks that exist outside of the balance sheet. Case in point: We've spotted 2 warning signs for Jiangsu Sinopep-Allsino Biopharmaceutical you should be aware of, and 1 of them is potentially serious.

江蘇中石化-艾爾西諾生物製藥的利息保障表明,它可以像克里斯蒂亞諾·羅納爾多在對陣14歲以下的守門員的比賽中進球一樣輕鬆地處理債務。但是我們必須承認,我們發現其將息稅前利潤轉換爲自由現金流會產生相反的效果。綜合上述所有因素,令我們震驚的是,江蘇中石油-艾爾西諾生物製藥能夠相當輕鬆地處理其債務。當然,儘管這種槓桿可以提高股本回報率,但它確實帶來了更多的風險,因此值得關注。毫無疑問,我們從資產負債表中學到的關於債務的知識最多。但歸根結底,每家公司都可以控制資產負債表之外存在的風險。一個很好的例子:我們發現了你應該注意的江蘇Sinop-Allsino生物製藥的2個警告信號,其中一個可能很嚴重。

Of course, if you're the type of investor who prefers buying stocks without the burden of debt, then don't hesitate to discover our exclusive list of net cash growth stocks, today.

當然,如果你是那種喜歡在沒有債務負擔的情況下購買股票的投資者,那麼請立即查看我們的獨家淨現金增長股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論